

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/733,134	12/10/2003	Robert M. Burk	17008DIV5CON4(AP)	7395
75	590 06/29/2004		EXAMINER	
ROBERT J. BARAN			SACKEY, EBENEZER O	
(T2-7H) ALLERGAN, INC.			ART UNIT	PAPER NUMBER
2525 Dupont D		1626		
Irvine, ČA 92612			DATE MAILED: 06/29/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/733,134	BURK, ROBERT M.				
Office Action Summary	Examiner	Art Unit				
	EBENEZER SACKEY	1626				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
•—						
, —						
Disposition of Claims						
4) ☐ Claim(s) 1-3 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-3 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ acc	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 12/10/03.	6) Other:	ателі Арріїсаноп (РТО-132)				

Application/Control Number: 10/733,134

Art Unit: 1626

DETAILED ACTION

Status of Claims

Claims 1-3 are pending.

Information Disclosure Statement

Receipt of the information disclosure statement filed on 12/10/03 is acknowledged and has been made of record. The signed copies of the 1449 are attached herewith.

Specification

The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain <u>a</u> patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1-3 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 4, 8 and 9 of prior U.S. Patent No. 6,303,658. This is a double patenting rejection.

Application/Control Number: 10/733,134

Art Unit: 1626

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim1-3 are rejected under 35 U.S.C. 102(b) as being anticipated by:

- (1) Burk (U.S.Patent number 5,545,665), see Example 13c in column 15.
- (2) Burk (U.S.Patent number 5,906,989) example 13c in column 14.
- (3) WO 95/18102, compound 13c on page 27.

Applicant claims a prostaglandin compound i.e. $7-[3\alpha-5\alpha-dihydroxy-2\beta-(3\alpha-methoxy-1E-octenyl)$ -cyclopentyl]-5Z-heptenamide compound, composition containing the compound and method of using the compound to treat ocular hypertension or glaucoma.

Burk '665' discloses said compound, 7-[3α-5α-dihydroxy-2β-(3α-methoxy-1E-octenyl)-cyclopentyl]-5Z-heptenamide composition containing the compound and method of treating ocular hypertension or glaucoma. See for example '665' column 3, lines 9-14, column 4, lines 24-29, column 7, the 15th compound, Example 13c.

Burk '989' discloses said compound, 7-[3α - 5α -dihydroxy- 2β -(3α -methoxy-1E-octenyl)-cyclopentyl]-5Z-heptenamide composition containing the compound and method of treating ocular hypertension or glaucoma. See for example column 3, lines 9-14, column 7, the 15^{th} compound, Example 13c.

Application/Control Number: 10/733,134

Art Unit: 1626

WO 95/18102 discloses said compound, 7-[3α - 5α -dihydroxy- 2β -(3α -methoxy-1E-octenyl)-cyclopentyl]-5Z-heptenamide. See compound 13c on page 27.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to E. Sackey whose telephone number is (703) 305-6889. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane, can be reached on (703) 308-4537. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

EOS June 25, 2004

Joseph K. McKane

Supervisory Patent Examiner
Art Unit 1626, Group 1600
Technology Center 1